Nifty
Sensex
:
:
17274.30
58065.47
386.95 (2.29%)
1276.66 (2.25%)

Pharmaceuticals & Drugs - Global

Rating :
50/99

BSE: 532321 | NSE: ZYDUSLIFE

419.90
04-Oct-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 414.00
  • 421.50
  • 405.70
  • 409.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4337423
  •  18005.96
  •  573.20
  •  319.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 41,429.52
  • 9.38
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,518.62
  • 0.61%
  • 2.46

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.96%
  • 8.02%
  • FII
  • DII
  • Others
  • 2.86%
  • 12.00%
  • 1.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.15
  • 5.01
  • 2.31

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.48
  • 3.32
  • 3.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.88
  • 5.09
  • 24.13

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.32
  • 21.11
  • 24.00

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.98
  • 3.64
  • 3.28

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.56
  • 14.61
  • 14.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Net Sales
4,072.70
4,001.80
1.77%
3,863.80
3,670.30
5.27%
3,655.00
3,633.00
0.61%
3,784.80
3,658.90
3.44%
Expenses
3,239.70
3,029.90
6.92%
3,146.10
2,820.80
11.53%
2,902.50
2,866.50
1.26%
2,924.00
2,845.10
2.77%
EBITDA
833.00
971.90
-14.29%
717.70
849.50
-15.52%
752.50
766.50
-1.83%
860.80
813.80
5.78%
EBIDTM
20.45%
24.29%
18.57%
23.15%
20.59%
21.10%
22.74%
22.24%
Other Income
65.90
31.60
108.54%
79.10
-30.40
-
60.80
27.20
123.53%
53.30
27.50
93.82%
Interest
34.30
27.30
25.64%
38.50
23.20
65.95%
31.10
27.10
14.76%
30.10
45.20
-33.41%
Depreciation
180.70
173.30
4.27%
185.40
175.30
5.76%
183.20
176.20
3.97%
184.80
174.60
5.84%
PBT
681.00
802.90
-15.18%
572.90
547.50
4.64%
599.00
590.40
1.46%
603.50
489.50
23.29%
Tax
118.40
157.40
-24.78%
109.20
-206.00
-
110.70
104.50
5.93%
100.00
100.00
0.00%
PAT
562.60
645.50
-12.84%
463.70
753.50
-38.46%
488.30
485.90
0.49%
503.50
389.50
29.27%
PATM
13.81%
16.13%
12.00%
20.53%
13.36%
13.37%
13.30%
10.65%
EPS
5.06
5.73
-11.69%
3.88
6.63
-41.48%
4.89
5.15
-5.05%
29.32
4.62
534.63%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
15,376.30
15,265.20
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
Net Sales Growth
2.76%
5.98%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
 
Cost Of Goods Sold
5,734.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
Gross Profit
9,641.60
10,508.20
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
GP Margin
62.70%
68.84%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
Total Expenditure
12,212.30
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
Power & Fuel Cost
-
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
129.70
124.40
% Of Sales
-
1.96%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
1.96%
Employee Cost
-
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
818.40
% Of Sales
-
14.27%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
12.87%
Manufacturing Exp.
-
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
897.30
% Of Sales
-
14.89%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
14.11%
General & Admin Exp.
-
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
302.70
342.20
% Of Sales
-
3.32%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
5.38%
Selling & Distn. Exp.
-
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
857.50
% Of Sales
-
9.00%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
13.49%
Miscellaneous Exp.
-
548.90
548.90
525.90
371.20
404.40
502.60
416.10
330.50
295.20
857.50
% Of Sales
-
3.60%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
2.48%
EBITDA
3,164.00
3,330.00
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
EBITDA Margin
20.58%
21.81%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
Other Income
259.10
235.40
47.40
117.10
208.50
133.00
147.10
116.60
57.20
85.90
38.40
Interest
134.00
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
168.70
Depreciation
734.10
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
PBT
2,456.40
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
Tax
438.30
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
Tax Rate
17.84%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
PAT
2,018.10
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
PAT before Minority Interest
1,884.30
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
Minority Interest
-133.80
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
PAT Margin
13.12%
14.38%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
PAT Growth
-11.27%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
 
EPS
19.71
21.45
21.04
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
Non-Current Liabilities
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
Secured Loans
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
Unsecured Loans
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
Long Term Provisions
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
Current Liabilities
7,839.40
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
Trade Payables
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
Other Current Liabilities
1,980.10
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
Short Term Borrowings
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
Short Term Provisions
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
Total Liabilities
26,699.60
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
Net Block
12,253.40
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
Gross Block
17,715.80
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
Accumulated Depreciation
5,291.80
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
Non Current Assets
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
Capital Work in Progress
661.00
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
Non Current Investment
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
Long Term Loans & Adv.
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
Other Non Current Assets
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
Current Assets
12,261.40
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
Current Investments
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
Inventories
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
Sundry Debtors
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
Cash & Bank
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
Other Current Assets
1,741.60
523.90
441.60
496.00
1,048.40
348.50
358.90
311.50
323.50
345.90
Short Term Loans & Adv.
1,207.30
741.40
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
Net Current Assets
4,422.00
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
Total Assets
26,699.60
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
2,104.10
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
PBT
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
Adjustment
-2,102.10
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
315.90
Changes in Working Capital
-351.50
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
Cash after chg. in Working capital
2,778.70
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
0.00
Cash From Investing Activity
1,154.40
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
Net Fixed Assets
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
Net Investments
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
Others
292.00
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
Cash from Financing Activity
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
Net Cash Inflow / Outflow
2,390.20
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
Opening Cash & Equivalents
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
Closing Cash & Equivalent
3,460.10
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
ROA
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
ROE
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
ROCE
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
18.21%
Fixed Asset Turnover
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
Receivable days
39.81
42.92
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
Inventory Days
42.81
38.08
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
Payable days
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
49.83
43.54
Cash Conversion Cycle
-84.02
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
65.78
74.05
Total Debt/Equity
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
Interest Cover
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29
8.98
5.79

News Update:


  • Zydus Lifesciences’ arm gets tentative nod for Amantadine Extended-Release Capsules
    4th Oct 2022, 14:36 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences’ arm gets nod to market Mirabegron Extended-Release Tablets
    3rd Oct 2022, 09:19 AM

    Mirabegron Extended-Release Tablets USP 25mg and 50mg had annual sales of $2.42 billion in the United States

    Read More
  • Zydus Lifesciences gets USFDA’s final nod to market Sildenafil for oral suspension
    1st Oct 2022, 10:43 AM

    Sildenafil for oral suspension is used to treat high blood pressure in the lungs

    Read More
  • USFDA completes inspection at Zydus Lifesciences’ arm’s unit with 2 observation
    30th Sep 2022, 14:51 PM

    None of these observations were related to data integrity

    Read More
  • Zydus Lifesciences launches Lenalidomide Capsules in US
    20th Sep 2022, 14:48 PM

    Lenalidomide is used to treat various types of cancers

    Read More
  • Zydus Lifesciences’ arm receives USFDA’s tentative approval for Sugammadex Injection
    16th Sep 2022, 12:26 PM

    Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Lenalidomide Capsules
    13th Sep 2022, 14:23 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences’ arm gets final approval, 180 days shared exclusivity from USFDA for Cariprazine Capsules
    12th Sep 2022, 14:36 PM

    Cariprazine Capsules had annual sales of $2.39 billion in the United States according to IQVIA MAT July 2022

    Read More
  • Zydus Lifesciences acquires rights to market MonoFerric injections in India, Nepal
    9th Sep 2022, 09:28 AM

    MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch

    Read More
  • Zydus Lifesciences gets positive Proof-of-Concept in Phase 2 clinical study of ‘ZYIL1’
    8th Sep 2022, 09:45 AM

    ZYIL1 was safe and well-tolerated and there were no Serious Adverse Events (SAE’s) observed in this Phase 2 trial

    Read More
  • Zydus Lifesciences recalls 1,116 boxes of Fulvestrant Injection in US market
    5th Sep 2022, 10:30 AM

    The company's US-based unit is recalling the affected lot due to Failed Impurities/Degradation Specifications

    Read More
  • Zydus Lifesciences gets two final approvals from USFDA for Venlafaxine, Pregabalin
    1st Sep 2022, 09:35 AM

    Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder

    Read More
  • Zydus Lifesciences commences Phase IV clinical trial for Desidustat in patients with CKD induced anemia
    30th Aug 2022, 12:28 PM

    The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Prochlorperazine Maleate tablets
    11th Aug 2022, 11:27 AM

    The group now has 320 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences - Quarterly Results
    10th Aug 2022, 13:12 PM

    Read More
  • USFDA conducts inspection at Zydus Lifesciences’ Moraiya manufacturing facility in Ahmedabad
    5th Aug 2022, 15:46 PM

    The inspection concluded with four Form 483 observations

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Empagliflozin Tablets
    5th Aug 2022, 10:23 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Ivermectin Cream
    4th Aug 2022, 18:00 PM

    The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad, India

    Read More
  • Zydus Lifesciences gets final nod to market Bisoprolol Fumarate tablets
    26th Jul 2022, 17:22 PM

    Bisoprolol Fumarate tablets had annual sales of $30 million in the United States

    Read More
  • Zydus Lifesciences receives final approval from USFDA for Norepinephrine Bitartrate Injection
    21st Jul 2022, 09:18 AM

    The drug will be manufactured at the group’s topical injectable manufacturing facility at Jarod, India

    Read More
  • Zydus Lifesciences’ arm gets USFDA’s final approval for Efinaconazole Topical Solution
    18th Jul 2022, 15:57 PM

    Efinaconazole is an azole antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes

    Read More
  • Zydus gets final approval from USFDA for Empagliflozin and Metformin Hydrochloride Tablets
    11th Jul 2022, 10:48 AM

    The drug will be manufactured at the group’s formulation facility at SEZ, Ahmedabad, India

    Read More
  • Zydus Lifesciences launches Sitaglyn and Siglyn for management of Type 2 diabetes
    8th Jul 2022, 18:03 PM

    The drug provides best in class achievement of Hemoglobin A1C goals with proven safety profile

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Lacosamide Injection
    30th Jun 2022, 16:58 PM

    The drug will be manufactured at the group’s injectables manufacturing facility at Jarod, India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.